摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-6-phenyl-4-hexenamide | 220588-75-0

中文名称
——
中文别名
——
英文名称
(E)-N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-6-phenyl-4-hexenamide
英文别名
——
(E)-N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-6-phenyl-4-hexenamide化学式
CAS
220588-75-0
化学式
C30H47NO3
mdl
——
分子量
469.708
InChiKey
LNSCYVDUZURFMI-OVMPAUEHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.81
  • 重原子数:
    34.0
  • 可旋转键数:
    14.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.7
  • 拓扑面积:
    69.56
  • 氢给体数:
    3.0
  • 氢受体数:
    3.0

反应信息

  • 作为反应物:
    描述:
    (E)-N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-6-phenyl-4-hexenamide四氧化锇 N-甲基吗啉氧化物 作用下, 以 四氢呋喃叔丁醇 为溶剂, 反应 4.0h, 生成 (2R,4S,5S)-N-[1(S)-(Cyclohexylmethyl)-2(R), 3(S)-dihydroxy-5-methylhexyl]-2-(cyclopropylmethyl)-4,5-dihydroxy-6-phenylhexanamide 、 (2R,4R,5R)-N-[1(S)-(cyclohexylmethyl)-2(R), 3(S)-dihydroxy-5-methylhexyl]-2-(cyclopropylmethyl)-4,5-dihydroxy-6-phenylhexanamide
    参考文献:
    名称:
    Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2P3 sites
    摘要:
    Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P-2- P-3 Sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, 1a and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P-2-P-3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P-2 Side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(98)80011-4
  • 作为产物:
    描述:
    3-(3-cyclopropyl-1-oxopropyl)-4(S)-phenylmethyl-2-oxazolidinone 在 lithium hydroxide 、 正丁基锂双氧水 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 二异丙胺N,N-二异丙基乙胺 作用下, 以 四氢呋喃正己烷乙腈 为溶剂, 反应 23.75h, 生成 (E)-N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-6-phenyl-4-hexenamide
    参考文献:
    名称:
    Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2P3 sites
    摘要:
    Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P-2- P-3 Sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, 1a and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P-2-P-3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P-2 Side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(98)80011-4
点击查看最新优质反应信息